secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2026-08-19T20:05:15+00:00
Accession:  0001193125-26-356877
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio submits to Australian ethics committee to begin Phase 1/2 trial for KRRO-121 in UCDs
--------------------------------------------------------------------------------

- Submission to Alfred Health Human Ethics Committee to start first-in-human Phase 1/2 trial of KRRO-121.
- KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide targeting hyperammonemia in Urea Cycle Disorders.
- Trial will evaluate safety, tolerability of escalating doses, and pharmacokinetics in healthy volunteers and UCD patients.
- Listed on ClinicalTrials.gov as NCT07773246.
- No clinical data released yet; first-in-human milestone for the program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/0001193125-26-356877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/krro-20260819.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-356877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer